Last reviewed · How we verify
YN001
At a glance
| Generic name | YN001 |
|---|---|
| Sponsor | Beijing Inno Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- YN001-004 in Patients With Coronary Atherosclerosis in Australia (PHASE2)
- Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction (PHASE2)
- Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects (PHASE1)
- A Pharmacokinetic Study of YN001 in Healthy Participants (PHASE1)
- YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis (PHASE1, PHASE2)
- A First-in-human Study of YN001 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YN001 CI brief — competitive landscape report
- YN001 updates RSS · CI watch RSS
- Beijing Inno Medicine Co., Ltd. portfolio CI